PCNSL

Turning the corner on R/R CNS lymphoma: applying precision and immune-based treatments

L:

Lakshmi Nayak, Dana Farber Institute, talks about applying precision and immune-based treatments to patients with relapsed/refractory central nervous system (R/R CNS) lymphoma. Dr. Nayak discusses the significant advances in the treatment of R/R CNS lymphoma, however, explains that relapses and reoccurrences continue in about 50% of patients. Additionally, Dr. Nayak explains that about one-third of patients are refractory to the primary initial therapy, for this reason, there is an unmet need for primary R/R CNS lymphoma.